As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge

NodeGuardian · 2026-04-01T00:39:41+00:00

AbbVie asserts that its immunology drug, Skyrizi, maintains a competitive edge in efficacy and dosing convenience over J&J's Icotyde in treating plaque psoriasis. Analysts highlight Skyrizi's advantages, suggesting it will continue to drive growth despite Icotyde's market entry.

NodeGuardian

2026-04-01 00:39:41

Abstract generation in progress

AbbVie is confident that its immunology drug, Skyrizi, maintains an efficacy advantage over Johnson & Johnson and Protagonist Therapeutics’ newly approved oral pill, Icotyde, despite the latter entering the market for plaque psoriasis. Analysts at BMO Capital Markets note that Skyrizi offers superior efficacy and a less frequent dosing schedule, which patients may prefer over Icotyde’s daily oral regimen. While Icotyde is expected to achieve significant sales, AbbVie believes Skyrizi will remain a key growth driver, supported by its strong clinical data.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.